Federico Mingozzi, PhD

Treasurer (2023-2026)

Federico Mingozzi, PhD, is the Chief Executive Officer of Nava Therapeutics. His career has been dedicated to developing safe and effective gene-based treatments for both genetic and acquired diseases. His academic research focused on understanding the interactions between gene therapy vectors and the host immune system, as well as the development and clinical translation of adeno-associated virus (AAV)-based gene therapies.

Dr. Mingozzi has played a leading role in pioneering gene therapy clinical trials for a range of conditions, including metabolic diseases, bleeding disorders, inherited forms of blindness, and neuromuscular diseases. This translational work expanded his expertise into delivery platform technologies, manufacturing, regulatory strategy, and clinical trial design. His transition from academia to industry further broadened his leadership scope and research interests.

Prior to his current role, he served as Chief Science & Technology Officer at Spark Therapeutics, where he led a team advancing a pipeline of gene therapies targeting the eye, liver, and central nervous system. This work included innovation in delivery and therapeutic modalities, as well as technical development, analytical development, and quality control.

At Nava Therapeutics, Dr. Mingozzi leads an organization focused on overcoming the limitations of non-viral delivery and advancing mRNA-based therapeutics. He is deeply committed to science, the development of transformative therapies for patients, and mentoring the next generation of gene therapy researchers.